TABLE 3.
Patient-Level Transitions in Lipid-Lowering Therapy Before and After 2013 Cholesterol Guideline
| Postguideline | Postguideline | Statin | Statin | ||||
| No Change | To Statin | To Nonstatin | To Both | No Treatment | Discontinuationa | Initiationb | |
| ASCVD (n = 301,440) | |||||||
| Statin | 109,751 (85.4) | - | 490 (0.4) | 1,872 (1.5) | 16,448 (12.8) | 16,938 (13.2) | - |
| Nonstatin | 4,439 (58.4) | 638 (8.4) | - | 774 (10.2) | 1,749 (23.0) | - | 1,412 (18.6) |
| Statin and nonstatin | 10,913 (67.4) | 3,470 (21.4) | 715 (4.4) | - | 1,095 (6.8) | 1,810 (11.2) | - |
| No treatment | 132,718 (89.0) | 14,520 (9.7) | 1,269 (0.9) | 579 (0.4) | - | - | 15,099 (10.1) |
| Total: 18,748 (6.2) | Total: 16,511 (5.5) | ||||||
| DM (n = 309,095) | |||||||
| Statin | 115,251 (85.7) | - | 616 (0.5) | 2,573 (1.9) | 16,121 (12.0) | 16,737 (12.4) | - |
| Nonstatin | 6,679 (58.1) | 1,063 (9.2) | - | 1,432 (12.5) | 2,332 (20.3) | - | 2,495 (21.7) |
| Statin and nonstatin | 14,522 (69.9) | 3,973 (19.1) | 960 (4.6) | - | 1,322 (6.4) | 2,282 (11.0) | - |
| No treatment | 119,955 (84.3) | 19,504 (13.7) | 1,915 (1.4) | 877 (0.6) | - | - | 20,381 (14.3) |
| Total: 19,019 (6.2) | Total: 22,876 (7.4) | ||||||
Note: Values are represented as number (%) unless noted otherwise.
a Based on sum of patients transitioning to either nonstatins or no treatment at 1 year.
b Based on sum of patients transitioning to either statins only or both statins and nonstatins at 1 year.
ASCVD = atherosclerotic cardiovascular disease; DM = diabetes mellitus.